Magdalena Kozielska

Groningen, GR 9747AG, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

A neural network model for the evolution of reconstructive social learning.

A neural network model for the evolution of reconstructive social learning.

Journal: Scientific reports
Published: September 03, 2024

A neural network model for the evolution of learning in changing environments.

A neural network model for the evolution of learning in changing environments.

Journal: PLoS computational biology
Published: August 24, 2023

The sex-specific factor SOA controls dosage compensation in Anopheles mosquitoes.

The sex-specific factor SOA controls dosage compensation in Anopheles mosquitoes.

Journal: Nature
Published: September 16, 2022

Erratum to: Translational Modeling in Schizophrenia: Predicting Human Dopamine D₂ Receptor Occupancy.

Erratum to: Translational Modeling in Schizophrenia: Predicting Human Dopamine D₂ Receptor Occupancy.

Journal: Pharmaceutical research
Published: February 16, 2016

Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy.

Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy.

Journal: Pharmaceutical research
Published: October 08, 2015

Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scale.

Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scale.

Journal: Journal of clinical psychopharmacology
Published: October 12, 2013

Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: a pharmacokinetic-pharmacodynamic modeling approach.

Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: a pharmacokinetic-pharmacodynamic modeling approach.

Journal: Pharmaceutical research
Published: July 10, 2013

Modelling and simulation of placebo effect: application to drug development in schizophrenia.

Modelling and simulation of placebo effect: application to drug development in schizophrenia.

Journal: Journal of pharmacokinetics and pharmacodynamics
Published: October 15, 2012

Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophrenia.

Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophrenia.

Journal: Schizophrenia research
Published: May 08, 2012

Pharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: the use of PANSS total score and clinical utility.

Pharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: the use of PANSS total score and clinical utility.

Journal: Schizophrenia research
Published: March 23, 2012

Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.

Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.

Journal: Schizophrenia research
Published: March 23, 2012

Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials.

Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials.

Journal: Clinical pharmacokinetics
Published: March 17, 2012
Showing 1-12 of 15

Last Updated: 09/26/2026